QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:EXAS

Exact Sciences (EXAS) Stock Forecast, Price & News

$65.94
-0.91 (-1.36%)
(As of 09/25/2023 ET)
Compare
Today's Range
$65.73
$67.35
50-Day Range
$65.94
$99.04
52-Week Range
$29.27
$100.77
Volume
1.52 million shs
Average Volume
1.93 million shs
Market Capitalization
$11.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$97.00

Exact Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
47.1% Upside
$97.00 Price Target
Short Interest
Bearish
4.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
1.38mentions of Exact Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.94 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.90) to ($1.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

111th out of 962 stocks

Medical Laboratories Industry

4th out of 23 stocks


EXAS stock logo

About Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Price History

EXAS Stock News Headlines

WARNING: Seven millionaires to trigger sudden market panic?
The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.
Exact Sciences
WARNING: Seven millionaires to trigger sudden market panic?
The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.
Citi Sticks to Its Buy Rating for Exact Sciences (EXAS)
Why Exact Sciences Stock Slumped Wednesday
Exact Sciences (EXAS) Q2 2023 Earnings Call Transcript
Exact Sciences Announces Second-Quarter 2023 Results
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Company Calendar

Last Earnings
8/01/2023
Today
9/25/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,400
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$97.00
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+47.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
14 Analysts

Profitability

Net Income
$-623,510,000.00
Pretax Margin
-18.87%

Debt

Sales & Book Value

Annual Sales
$2.08 billion
Book Value
$17.13 per share

Miscellaneous

Free Float
178,316,000
Market Cap
$11.91 billion
Optionable
Optionable
Beta
1.41

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Kevin T. ConroyMr. Kevin T. Conroy (Age 57)
    Chairman of The Board & CEO
    Comp: $1.54M
  • Mr. Jeffrey T. Elliott CFA (Age 45)
    Exec. VP & CFO
    Comp: $518.13k
  • Ms. Sarah CondellaMs. Sarah Condella (Age 42)
    Exec. VP of HR
    Comp: $742.76k
  • Mr. Everett V. CunninghamMr. Everett V. Cunningham (Age 57)
    Chief Commercial Officer
    Comp: $1.34M
  • Dr. Jorge A. Garces Ph.D. (Age 51)
    Chief Science Officer
  • Ms. Megan Jones
    Associate Mang. of Investor Relations
  • Mr. Tim Caprez
    Chief Compliance Counsel & VP
  • Mr. James HerriottMr. James Herriott (Age 43)
    Sr. VP, Gen. Counsel & Sec.
  • Mr. Vic Parker
    Head of Sales
  • Ms. Kristen Weiler
    VP of Marketing













EXAS Stock - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price forecast for 2023?

14 equities research analysts have issued 1 year price objectives for Exact Sciences' shares. Their EXAS share price forecasts range from $60.00 to $130.00. On average, they anticipate the company's stock price to reach $97.00 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2023?

Exact Sciences' stock was trading at $49.51 on January 1st, 2023. Since then, EXAS shares have increased by 33.2% and is now trading at $65.94.
View the best growth stocks for 2023 here
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our EXAS earnings forecast
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) issued its earnings results on Tuesday, August, 1st. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.05. The medical research company earned $622.10 million during the quarter, compared to analyst estimates of $601.14 million. Exact Sciences had a negative trailing twelve-month return on equity of 14.08% and a negative net margin of 18.76%. The business's revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.94) earnings per share.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences updated its FY 2023 earnings guidance on Wednesday, June, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.40 billion-$2.40 billion, compared to the consensus revenue estimate of $2.42 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (3.96%), Capital World Investors (3.76%), Baillie Gifford & Co. (2.53%), Artisan Partners Limited Partnership (1.96%), Geode Capital Management LLC (1.49%) and Sumitomo Mitsui Trust Holdings Inc. (1.47%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy and Sarah Condella.
View institutional ownership trends
.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $65.94.

How much money does Exact Sciences make?

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $11.91 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.

How many employees does Exact Sciences have?

The company employs 6,400 workers across the globe.

Does Exact Sciences have any subsidiaries?
The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More
How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -